DB22146InvestigationalCell transplant therapies
Chimeric Antigen Receptor T-cells is under investigation in clinical trial NCT05225363 (Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer).
- Mechanism
- Curator reviewed
Pharmacologically active on B-cell receptor CD22, Receptor tyrosine-protein kinase erbB-2, and B-lymphocyte antigen CD19
- Also known as
- CAR - T · CAR T · CAR T cell · CAR T cells · CAR T-cell
Resolves to
What you can answer from here — as of August 13, 2026
7Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Chimeric antigen receptor T-cells, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account